Blocking TRPV1 suppresses morphine-induced c-fos expression, reduces opioid tolerance and opioid-induced hyperalgesia, attenuates opiate-mediated conditioned place preference (CPP) behaviors, decreases anxiety-like behaviors after abstinence from morphine, alleviates negative emotions during withdrawal, and suppresses the motivational properties of morphine and its reinstatement or relapse54–57. Here, FOS is linked to Anxiety.